Effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation

Conference · Tue Nov 01 04:00:00 EST 1983 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

OSTI ID:5300770

Danoff, B F ^[1]; Goodman, R L; Glick, J H; Haller, D G; Pajak, T F

---

1. Univ. of Pennsylvania School of Medicine, Philadelphia

From 1978 to 1981, 46 patients received primary radiotherapy following excisional biopsy and axillary staging procedure for Stages I and II carcinoma of the breast. The patients were divided into 2 groups: 27 patients who received radiation and completed 12 cycles of adjuvant chemotherapy (CMF or CMFP) and 19 patients who received radiation alone. All patients received radiation to the breast and regional nodes (4600 to 5000 rad) and a boost to the site of the primary tumor (1500 to 2000 rad). Median follow-up from completion of radiation was 26 months in the non-adjuvant and 24 months in the adjuvant group with a range of 12 to 49 months. Cosmesis was judged to be good to excellent in 89% (17/19) of the patients receiving radiation alone and 81% (22/27) of the patients receiving adjuvant chemotherapy. Fair to poor cosmesis in the adjuvant group was attributed primarily to increased fibrosis and reduction of breast size. The single complication for which there was an increased incidence in the adjuvant group was arm edema (22 vs. 0%). The incidence of arm edema was unrelated to T stage, type of axillary surgical procedure, number of positive nodes, addition of prednisone or sequencing of chemotherapy.

• OSTI ID: 5300770
• Conference Information: Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 9:11
• Country of Publication: United States
• Language: English

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKYLATING AGENTS
ANTIMETABOLITES
AZINES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
CARCINOMAS
CHEMOTHERAPY
DISEASES
DRUGS
EDEMA
ELECTROMAGNETIC RADIATION
ENDOXAN
ENERGY RANGE
FIBROSIS
FLUOROURACILS
GLANDS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
IMMUNOSUPPRESSIVE DRUGS
IONIZING RADIATIONS
LYMPH NODES
LYMPHATIC SYSTEM
MAMMARY GLANDS
MEDICINE
METHOTREXATE
MEV RANGE
MEV RANGE 01-10
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATHOLOGICAL CHANGES
PATIENTS
PYRIMIDINES
RADIATION EFFECTS
RADIATIONS
RADIOINDUCTION
RADIOLOGY
RADIOTHERAPY
SIDE EFFECTS
SYMPTOMS
THERAPY
URACILS
X RADIATION